All of these platitudes are the same as was said in 2022, 2021, 2020, 2019 and so on. Great news is always around the corner and then the next corner and the next.
I have a feeling even an MHRA approval won’t result in more than the $2+ a share we attained almost 3 years ago on mere rumor of TLD. It could be more but one can never underestimate the inability of NWBO management to follow up on good news and make it work for shareholders.
Maybe this time will be different but if the (already late when it’s nearly 3 years from DL) MHRA approval fails to impress everyone will say oh, that two continent strategy has changed and it all rides on the FDA after all!
Market Data 
Markets 
AI
